159 related articles for article (PubMed ID: 34275438)
1. The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.
Nesic M; Sønderkær M; Brøndum RF; El-Galaly TC; Pedersen IS; Bøgsted M; Dybkær K
BMC Cancer; 2021 Jul; 21(1):829. PubMed ID: 34275438
[TBL] [Abstract][Full Text] [Related]
2. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
3. Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B; Lee H; Cho J; Yoon SE; Kim SJ; Park WY; Kim WS; Ko YH
Front Oncol; 2021; 11():628807. PubMed ID: 33777778
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Broccoli A; Casadei B; Chiappella A; Visco C; Tani M; Cascavilla N; Conconi A; Balzarotti M; Cox MC; Marino D; Goldaniga MC; Marasca R; Tecchio C; Patti C; Musuraca G; Devizzi L; Monaco F; Romano A; Fama A; Zancanella M; Paolini R; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Oncologist; 2019 Sep; 24(9):1246-1252. PubMed ID: 30940746
[TBL] [Abstract][Full Text] [Related]
5. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
[TBL] [Abstract][Full Text] [Related]
6. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.
Fangazio M; Ladewig E; Gomez K; Garcia-Ibanez L; Kumar R; Teruya-Feldstein J; Rossi D; Filip I; Pan-Hammarström Q; Inghirami G; Boldorini R; Ott G; Staiger AM; Chapuy B; Gaidano G; Bhagat G; Basso K; Rabadan R; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050029
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
11. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
12. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Hilton LK; Ngu HS; Collinge B; Dreval K; Ben-Neriah S; Rushton CK; Wong JCH; Cruz M; Roth A; Boyle M; Meissner B; Slack GW; Farinha P; Craig JW; Gerrie AS; Freeman CL; Villa D; Rodrigo JA; Song K; Crump M; Shepherd L; Hay AE; Kuruvilla J; Savage KJ; Kridel R; Karsan A; Marra MA; Sehn LH; Steidl C; Morin RD; Scott DW
J Clin Oncol; 2023 Sep; 41(25):4164-4177. PubMed ID: 37319384
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma.
Nesic M; El-Galaly TC; Bøgsted M; Pedersen IS; Dybkær K
Expert Rev Hematol; 2020 Jun; 13(6):655-668. PubMed ID: 32293210
[TBL] [Abstract][Full Text] [Related]
14.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
16. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
19. Relapse timing is associated with distinct evolutionary dynamics in DLBCL.
Hilton LK; Ngu HS; Collinge B; Dreval K; Ben-Neriah S; Rushton CK; Wong JCH; Cruz M; Roth A; Boyle M; Meissner B; Slack GW; Farinha P; Craig JW; Gerrie AS; Freeman CL; Villa D; Crump M; Shepherd L; Hay AE; Kuruvilla J; Savage KJ; Kridel R; Karsan A; Marra MA; Sehn LH; Steidl C; Morin RD; Scott DW
medRxiv; 2023 Mar; ():. PubMed ID: 36945587
[TBL] [Abstract][Full Text] [Related]
20. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
Rushton CK; Arthur SE; Alcaide M; Cheung M; Jiang A; Coyle KM; Cleary KLS; Thomas N; Hilton LK; Michaud N; Daigle S; Davidson J; Bushell K; Yu S; Rys RN; Jain M; Shepherd L; Marra MA; Kuruvilla J; Crump M; Mann K; Assouline S; Connors JM; Steidl C; Cragg MS; Scott DW; Johnson NA; Morin RD
Blood Adv; 2020 Jul; 4(13):2886-2898. PubMed ID: 32589730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
